AGIANA PHARMACEUTICALS AS
Signals
- Driftsunderskudd 2025 Siste driftsresultat er negativt (−15,5 mill kr).
AGIANA PHARMACEUTICALS AS is registered as a limited company in Oslo, Oslo with organisation number 927648946. The business is classified under research and experimental development on natural sciences and engineering (NACE 72.100). The company was incorporated in 2021. Registered share capital is NOK 37,000, divided into 37322 shares. The company's stated purpose is: “Utvikling og kommersialisering av legemidler.”. The most recent filed accounts, for the 2025 financial year, show NOK 2.9m in revenue and NOK −15.5m in operating profit.
Former names: NEWCO INVEN2 II AS
Key figures · 2025
Financial health · 2025
Who owns AGIANA PHARMACEUTICALS AS?
AGIANA PHARMACEUTICALS AS has 4 registered shareholders:
- DART NEURO SCIENCE LLC 49.1%
- INVEN2 AS 37.1%
- JONAS SKOGESTAD 8.3%
- JAN MAGNUS ARONSEN 5.5%
Frequently asked questions about AGIANA PHARMACEUTICALS AS
Who owns AGIANA PHARMACEUTICALS AS?
DART NEURO SCIENCE LLC is the largest registered owner, with 49.1%.
What is the revenue of AGIANA PHARMACEUTICALS AS?
AGIANA PHARMACEUTICALS AS had revenue of NOK 2.9m in 2025.
Who is the general manager of AGIANA PHARMACEUTICALS AS?
Rizwan Iqbal Hussain is registered as general manager of AGIANA PHARMACEUTICALS AS.
Where is AGIANA PHARMACEUTICALS AS based?
AGIANA PHARMACEUTICALS AS has its business address in Oslo.
Property
292 companies are registered at this address.
The address this company is registered at, from the company register and matched against the cadastre. It does not say who owns the property — a company may be a tenant, and the address is often its accountant's. Source: Brønnøysundregistrene and © Kartverket.
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 02.09.2026.